{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-24-000013","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.223423+00:00","generated_at":"2026-06-05T18:10:39.951560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin reports record FY2023 revenue $2.42B (+15% YoY); non-GAAP EPS $2.08 (+36% YoY)","bullets":["FY2023 total revenues $2.42B (+15% YoY); GAAP diluted EPS $0.87 (+16% YoY); non-GAAP diluted EPS $2.08 (+36% YoY).","VOXZOGO net revenues $146M in Q4'23 (+118% Q/Q) and $470M for FY'23 (+178% YoY); 2,613 children treated at year-end.","Q4'23 total revenues $646.2M (+20% YoY); GAAP net income $20.4M vs $0.2M loss in Q4'22.","2024 guidance: double-digit total revenue growth, non-GAAP operating margin expansion, EPS growing faster than revenue.","FDA approved VOXZOGO for children under 5; ~70% of new US starts from that age group in Q4'23."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-24-000013","json":"https://secwatch.observer/filing/0001048477-24-000013.json","markdown":"https://secwatch.observer/filing/0001048477-24-000013.md","text":"https://secwatch.observer/filing/0001048477-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/0001048477-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/bmrn-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:10:39.951560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1acb6d749227887ea3600bba857cf1a96a4221ff","claim":"BIOMARIN PHARMACEUTICAL INC reported fourth quarter and full year ended December 31, 2023 results: revenue $646.2 million, net income $20.4 million, EPS $0.11. Guidance reaffirmed.","evidence_excerpt":"plans and convertible debt in periods when they are dilutive under Non-GAAP. nm Not meaningful Financial Highlights: • Total Revenues for the fourth quarter of 2023 were $646.2 million, an increase of 20% compared to the same period in 2022. The increase in Total Revenues was primarily attributed to higher VOXZOGO sales volume driven by new patients initiating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000013/0001048477-24-000013-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$646.2 million"},{"label":"Net income","value":"$20.4 million"},{"label":"EPS","value":"$0.11"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}